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This article  applies  concepts  from  health  economics  to address  what  is  the  “right”  amount  of  chemother-
apy  in non-curable  disease.  A  health  economics  perspective  is beneﬁcial  because  it forces  a  focus  on
objectives  and  constraints.  We  review  and  apply  the  concepts  of “Choice  of  Comparator”,  “Use  of QALYs”
and  “Equating  Marginal  Beneﬁt  to Marginal  Cost”,  demonstrating  their  ﬁt for  purpose  when  consider-
ing  the optimal  amount  of  chemotherapy  for non-curable  disease.  Many  efforts  underway  to  improve
healthcare  can  be  viewed  as applications  of these  key economic  principles.  The  true  value  is in  the con-
cepts  themselves  and  not  in  the  associated  calculations.  Given  the  difference  between  a population  and
a patient  perspective,  different  “optimal”  amounts  of  chemotherapy  may  exist.  For many,  however,  best
may not  be most.  Optimal  decisions  may  vary  depending  on  whether  the  goal  of treatment  is  to maximize
hope  or  health.
© 2016  Published  by Elsevier  Ltd.
1. Introduction
In a recent Forbes post entitled, “The FDA Is Basically Approv-
ing Everything”, Matthew Herper argues that the Food and Drug
Administration’s approval rate for new drugs is over 95% [1] in
sharp contrast to when it “once approved as few as 40% of new
drugs”[2]. This trend produces pressure around the world for
healthcare providers to prescribe and healthcare payers to fund
these new products. There is agreement throughout medicine and
especially in oncology that the current rate of growth in healthcare
expenditures is unsustainable [3,4]. Recently published warnings
have appeared in both general and specialty medical journals [5,6].
Experts note that the direct medical costs of cancer in the USA have
increased from nearly $27 billion in 1990 [7] to more than $90 bil-
lion in 2008 [8] more than two-fold increase even after adjusting for
inﬂation [9]. Smith and Hillner [4] report that annual direct costs in
the USA for cancer care are projected to increase by over 66% from
$104 billion in 2006 to over $173 billion in 2020 [4,10].
∗ Corresponding author.
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In cancer, there has been a pronounced focus on the cost of
drugs in relation to their clinical beneﬁts. Bach [11] observed that
spending from 1997 to 2004 on Medicare’s Part B drugs, “a cate-
gory dominated by drugs used to treat cancer”, increased by 267%
compared with overall Medicare spending which increased by 47%
during the same period. The problem of skyrocketing drug costs is
compounded by evidence suggesting that increased expenditures
are producing only minimal gains in terms of decreases in mortality
and increases in quality of life [11]. In other words, healthcare pay-
ers are paying more and getting less [12]. In her editorial, “Why do
drug companies charge so much? Because they can”, Marcia Angell
observes that “Unlike every other advanced country, the United
States permits drug companies to charge patients whatever they
choose” [13].
Although the USA has taken steps to prevent the simultane-
ous examination of both drug costs and patient outcomes [11,14],
other countries have embraced methods from health economics to
address the challenge of introducing controls in an attempt to curb
healthcare spending [15–17]. First and foremost, cost-effectiveness
analysis (CEA) has been implemented in a variety of settings to help
with “smart shopping” for cancer drugs. However, there are other
health economics concepts that can help, especially with address-
http://dx.doi.org/10.1016/j.jcpo.2016.05.002
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ing the question of chemotherapy. This paper describes and then
applies three principles from health economics to consider the
“right” amount of chemotherapy for non-curable disease.
2. Principles
In this section we describe the economic principles we will
demonstrate later in the Application section. The three key prin-
ciples are
1) To compare treatment options, a comparator is needed;
2) Quality Adjusted Life Years (QALYs) are useful when considering
both quality and length of life;
3) Optimal care occurs when the marginal beneﬁt equals the
marginal cost of care.
We  now describe and explain each principle in more detail.
2.1. To compare treatment options, a comparator is needed
An essential part of any evaluation is the choice of a com-
parator. In economic evaluations of healthcare interventions and
treatments, “something new” is often compared to “usual care”. In
CEA, the extra costs (C) are compared to the extra effects (E)
with C  computed as the difference between the expected costs
of the new treatment (CNT) and the expected costs of usual care
(CUC); E  is computed in a similar fashion using a patient outcome
chosen to be the Effect variable. The term “expected” is used in the
statistical sense, where outcomes are weighted by their respective
probabilities of occurrence. For example, with a new drug there
might be a 50% chance of living 9 more months and a 50% chance
of living 1 more month. The expected effect of the new treatment
(ENT) is
ENT = ½(9months) + ½(1month) = 5 months.
If patients receiving usual care are expected to live 4 months,
then E  = ENT − EUC = 5–4 = 1 more month.
Simply knowing the new treatment’s expected effect (ENT)—or
expected cost (CNT)—is not enough to do comparative analysis,
such as economic evaluation. This is because the calculation of E
involves two  components (i.e., ENT and EUC) as does the calculation
of C. In addition, the choice of a different comparator frequently
yields different estimates of C  and E. For example, if usual care
instead were associated with an expected patient outcome of 7
months of life, then E  = ENT − EUC = 5–7 = −2 (i.e. 2 less months).
Thus, CEA relies on four expected values for the estimation of C
and E  to inform policy and practice decisions. This is impossible
to do without a choice of comparator.
An appropriate comparator has a large impact on the ﬁnding
of effectiveness and ‘value for money’ of a treatment. Traditionally,
palliative care interventions as ‘usual care’ have not been compared
against chemotherapy for best care in end of life. However, where
they have, there is evidence for the potential of improved quality
of life (and sometimes even improved life expectancy [18]).
2.2. Quality adjusted life years (QALYs) consider both quality and
length of life
Health economists often study the efﬁciency of different ways
to accomplish an objective. When considering toxic treatments for
incurable disease, a reasonable objective could be to maximize an
outcome with quality of life (qol) and length of life (lol) dimensions.
In these circumstances, health economists use the quality adjusted
life year (QALY) which is equal to the product of qol and lol.  The qol
variable is called a “utility weight” and generally ranges between
0 (death) and 1 (perfect health) [19]. When QALYs are taken as
the outcome of interest, the resulting economic evaluation is often
described as a cost-utility analysis [20].
In these cases, the extra effects are calculated as extra
QALYs (QALYs). For example, a complete course of highly toxic
chemotherapy may allow patients to live 6 months on average with
a quality of life utility score of 0.60. Perhaps with good palliative
management patients can be expected to live 4.5 months with a
quality of life utility score of 0.80. The additional QALYs from the
new chemo are calculated as
QALYs = QALYsnewchemo − QALYspalliativecare.
TheQALYsnewchemo = qolnewchemo × lolnewchemo
= 0.60(½year) = 0.30QALYs.
This is the same as the result from the calculation of
QALYspalliativecare = qolpalliativecare × lolpalliativecare
= 0.80(0.375 year) = 0.30QALYs.
Thus, QALYs = 0. QALYs are a relevant way  to consider differ-
ent amounts of chemotherapy, especially with non-curable disease.
However, some critics argue that the QALY may not capture ade-
quately quality of life at the end of life, which is relevant for the
majority of high-cost cancer drugs that provide limited gains in life
extension in the last year of life [21]. To reach a decision about the
optimal amount of chemo, marginal beneﬁts and marginal costs
must be considered.
2.3. Optimal is where marginal beneﬁt equals marginal cost
To maximize Net Beneﬁt (NB), which is the difference between
Total Beneﬁts (TB) and Total Costs (TC), it is necessary to con-
sider marginal beneﬁt (MB) and marginal cost (MC). The term
“marginal” describes the resulting “extra” for very small changes in
consumption or use. Technically, NB = TB − TC and the quantity that
maximizes NB is one such that MB  = MC.  Intuitively, if more chemo
would add beneﬁt greater than its additional costs (i.e., MB > MC)
then one should consume more chemo. Alternatively, if the addi-
tional cost of more chemo is greater than the additional beneﬁt (i.e.,
MB < MC), it does not makes sense to consume more (it makes sense
to consume less). An optimal amount occurs when MB = MC,  as the
gain in beneﬁt from doing a bit more or a bit less equals the increase
in costs (so the gain in NB is zero). Although traditionally beneﬁts
and costs are thought of in monetary units, it is only necessary that
they be in the same units. For example, beneﬁts and costs could
be considered in terms of usefulness, satisfaction, energy or effort.
Regardless of the units employed, the optimal quantity of chemo
is the level at which MB  = MC.  This simple rule can lead to counter-
intuitive recommendations when applied; for example, the best
amount of treatment may  not be most amount of treatment.
3. Application
Next, we apply the principles described in the previous section
to analyze what is the right amount of chemotherapy in non-
curable disease. We  assume a patient can receive an amount of
chemo (chemo) for a non-curable disease ranging from 0% and 100%
of the patient’s remaining time. The optimal level of chemo can
differ by perspective. While applying the economic principles, we
illustrate contrasts between a population and an individual per-
spective.
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3.1. The choice of comparator and the creation of expectations
We  begin by considering patients whose usual care involves
full chemo for their non-curable disease (i.e., chemo = 100%). There
are other treatments that could be considered for non-curable dis-
ease. We  label such a treatment alternative “new treatment” (i.e.,
chemo < 100%). As noted above, economic analysis considers E
based on new treatment vs. usual care. Table 1 presents hypothet-
ical evidence with which E  can be computed.
Based on the ﬁrst row of Table 1, with usual care, there is a 50%
chance of living 9 months and a 50% chance of living 1 month, so
the expected outcome is 5 months (as computed in the previous
section). Alternatively, patients receiving new treatment have an
expected outcome that can be computed as ¾ (4 months) + ¼ (2
months) = 3.5 months, so E  = ENT − EUC = 3.5–5 = 1.5 less months.
Expected outcome (and therefore E) is a population concept
not an individual concept. The difference in population vs. indi-
vidual perspective can be understood in the interpretation of the
last column. The “expected outcome” of 5 months does not mean
patients can expect to live 5 months; in fact, 0% of patients receiving
usual care will live 5 months, even though the expected outcome
is 5 months. The expected outcome is useful when considering a
population of patients. Of 1000 patients treated with usual care,
500 will live 9 months and 500 will live 1 month for a total
gain of 4500 + 500 = 5000 months. In contrast, we expect that 1000
patients treated with new treatment will yield 750 patients liv-
ing 4 months and 250 patients living 2 months for a total gain
of 3000 + 500 = 3500 months. From a population perspective new
treatment provides 3500−5000 = 1500 less months for a popula-
tion of 1000 patients or 1500/1000 = 1.5 less months per patient.
Thus, the expected value is a useful concept for considering the
effect of policy decisions on a population of patients. However, it
is possible that not a single patient will experience the “expected”
effect of treatment.
Patient-based decisions may  involve other considerations
besides maximizing expected outcome. For example, what if a
patient wants to be present at an important event 6 weeks in the
future? In this case, the new treatment is optimal, since there is a
50% chance this will not happen with the choice of usual care. With
usual care, for every patient who lives 9 months there is a patient
who dies at 1 month (before the important event 1.5 months away).
With new treatment, all patients survive at least 2 months. Looking
at the “bad case” scenario in Table 1, from a population perspective,
the two treatment options have the same expected value; however,
from a patient perspective being twice as likely (50% vs. 25%) to live
half as long (1 month vs. 2 months) may  not be perceived as equiva-
lent. And for some wanting to minimize the possible loss in a worst
case scenario, the new treatment is actually better than usual care
(2 months vs. 1 month). Research on end of life care is rich in exam-
ples of where the maximization of expected health may  not be the
only objective (e.g., the application of prospect theory [22,23] and
the implications of valuing hope [24–26], etc.). For many patients,
quality of life is an important consideration.
3.2. Quality adjusting life years (QALYs)
When applying the concept of QALYs to the choice of how much
chemotherapy for non-curable disease, we assume that length of
life (lol) increases at the expense of decreased quality of life (qol).
This trade-off can be visualized with treatment options A through
E on the downward sloping solid line in Fig. 1.
In this example, the goal of maximizing QALYs occurs with the
optimal treatment option labeled “Opt”, as can be seen on the
dashed curve in Fig. 1. For patients currently receiving treatment
option B, a longer life with lower quality of life yields more QALYs;
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Fig. 1. The trade-off of longer life with lesser quality of life.
however, for patients receiving treatment option C, a shorter life
with more quality of life yields more QALYs.
The dashed upside down curve in Fig. 1 shows the QALYs from
each treatment option (Options B and C are at the same height of
0.30 since they yield the same number of QALYs). The maximum
QALYs a patient can experience occurs where the slope of the QALYs
curve is zero. At this point, with a little more lol or a little less lol,
no additional QALYs are gained. The optimal condition can also be
written as
 = −1
where  is the ratio of the percentage change in qol divided by the
percentage change in lol.1 When considering the treatment options
in Section 2.2, if we  assume that they represent options along a line
(like that in Fig. 1), we can calculate the slope as
qol/lol  = (0.60–0.80)/(0.500–0.375) = −0.2/0.125 = −1.6.
The  value at the point2 for new chemo where lol = 0.5 years
and qol = 0.60 is −1.6 × 0.5/0.6 = −1.33. The  value at the
point for palliative care where lol = 0.375 years and qol = 0.80
is −1.6 × 0.375/0.8 = −0.75. Since neither newchemo nor
palliativecare = −1, this means both palliative care and new chemo
treatment options can be improved upon; however, the direc-
tion for improvement differs. Since newchemo = −1.33 < −1, this
means there will be a 1.33% loss in qol with a 1% gain in lol.  This
indicates reducing lol to gain qol is optimal. In contrast, since
palliativecare = −0.75 > −1, there will be a 0.75% loss in qol from a 1%
gain in lol.  This indicates increasing lol while losing qol is optimal
because there is an overall gain in QALYs. In general, a simple
rule to determine the overall percentage change in QALYs from
a percentage change in lol is QALY,lol = (1 + qol,lol).3 Thus, when
qol,lol for new chemo = −1.33, increasing lol will lead to an overall
decrease in QALYs (since the decrease in qol will be proportionally
greater than the increase in lol).  In contrast, when qol,lol for
palliative care = −0.75, increasing lol will lead to an overall increase
1 As QALYs = qol × lol,  and we have assumed qol is a function of lol,  this means the
optimal lol sets QALYs/lol = (qol/lol × lol + qol) = 0. Dividing both sides by qol,
the  optimal lol satisﬁes the equation (qol/lol × lol/qol + 1) = 0. This can then be
simpliﬁed to (% qol)/(% lol) = −1 where% qol = qol/qol and % lol = lol/lol.
2 The expression for  can be written in terms of a slope and a point. For
example, since  = (qol/qol)/(lol/lol)  this means  = (qol/lol) × lol/qol,  so
  = slope × lol/qol.
3 For small changes, QALY = qol × lol + lol × qol,  so
(QALY)/(lol  × qol) = (qol × lol + lol × qol)/(lol × qol). Simplifying, % QALY = %
qol  +% lol. After factoring out, (% QALY/% lol) = 1 + (% qol/% lol).
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Table  1
Hypothetical evidence on hypothetical treatment options.
Outcome in good case (probability) Outcome in bad case (probability) Expected outcome
Usual Care of chemo = 100% 9 months (50%) 1 month (50%) EUC = 5 months
New  Treatment of chemo < 100% 4 months (75%) 2 month (25%) ENT = 3.5 months
Difference 1.5 months 0 E = −1.5 months
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Fig. 2. Optimal choices occur where Marginal Beneﬁt equals Marginal Cost.
in QALYs (since the decrease in qol will be proportionally less
than the increase in lol).  Only when qol,lol = −1, does QALY,lol = 0,
resulting in QALY = 0.4
While the mathematical process to calculate QALYs does not dif-
fer at the population and patient levels, the actual value of the QALY
(and treatment implications) may. For one type of patient, chemo
may  be consistent with treatment options like A or B in Fig. 1. How-
ever, for another type of patient, chemo may  be consistent with
treatment options like C, D or E in Fig. 1. If treatment response is
heterogeneous,  may  differ by patient, and so too will the attrac-
tiveness of additional chemo. Likewise, a patient may  ascribe a qol
weight that is different from the population average. Even different
countries have different utility weights for the same health state.
For example, nearly 90% of all qol weights for the UK vs. the US vary
by ≥ 0.10 (based on author calculations using the EQ-5D-5L) [27].
Needless to say, decisions to maximize QALYs at a population level
may  not be congruent with decisions to maximize an individual’s
QALYs, even if  is used for guidance. For example, prospect theory
assumes that patients value outcomes not in absolute terms, but
as deviations from their point of reference; different people may
have different reference points (leading to different optimal levels
of chemo) [22,23].
3.3. Marginal beneﬁt (MB) equals marginal cost (MC)
Additional beneﬁts usually come at an additional cost. When
considering additional chemo for non-curable disease, one must
ask, “When is enough enough?” The answer from economics is that
the best amount of chemo is the amount that maximizes Net Ben-
eﬁt; this amount of chemo equates Marginal Beneﬁt with Marginal
Cost (i.e., MB  = MC). Marginal is the slope of the Total or the result
of doing a bit more (or less). It can be calculated as the ﬁrst deriva-
tive of the Total. Fig. 2 illustrates these points with two graphs. The
upper graph in Fig. 2 shows Net Beneﬁt (as a dotted upside down
4 If QALY,lol = 0, this means % QALY/% lol = 0, so % QALY = 0; therefore,
QALY = 0.
curve), Total Beneﬁt (as a solid line) and Total Cost (as a heavy
dashed line).
The slopes of the Total Beneﬁt and the Total Cost curves are
the Marginal Beneﬁt and the Marginal Cost curves, respectively.
The Marginal curves are plotted in the lower graph in Fig. 2, MB
as a solid curve and MC  as a heavy dashed line. The vertical line
at chemo = 0.175 indicates the optimal amount of chemo where
MB = MC.  While this point is neither where Total Costs are min-
imized nor where Total Beneﬁts are maximized, it is where the
patient receives the most NB. Thus, economic analysis is able to
distinguish between the most amount of chemo, the least amount
of chemo and the best amount of chemo by considering the MB  and
MC of chemo for non-curable disease.
The mathematical process to calculate MB  and MC  does not dif-
fer at the population and patient levels; however, the actual value of
the marginal values may  vary to the extent that the formulations
of Total Beneﬁt and Total Cost vary between a population and a
patient. Also, as noted earlier, beneﬁts and costs are usually consid-
ered in monetary units, but they also can be thought of in terms of
usefulness, satisfaction, energy or effort. A healthcare payer taking
a population perspective might consider the MB  and MC  of chemo
for non-curable disease much differently from a patient. Regardless
of the units employed, the optimal quantity of chemo is the level at
which MB = MC.  Likewise, if treatment response is heterogeneous,
MB and MC  may  differ by patient, and so too will the attractiveness
of additional chemo. Of course, it is also possible for MB and MC  to
differ by country [23].
4. Discussion
4.1. Implications
When considering the “right” amount of chemo for non-curable
disease, health economics principles can be useful. The three main
concepts that we  reviewed and applied involved the importance of
(1) a comparator; (2) using QALYs and (3) treating until MB = MC.
The applications of these principles produced insights like
1) 100% chemo is one choice that must be compared to another
option having its own expected costs and effectiveness, since
there is never just one option from an economic perspective;
2) Increasing length of life is not always synonymous with increas-
ing quality-adjusted life; and
3) The best amount of treatment can be neither the most nor the
least amount of treatment.
The implications for choice of care (e.g., palliative care vs. chemo
care) are clear. Considering only one option for care for non-curable
disease is not a helpful way  to facilitate an informed choice. Consid-
ering only one dimension of outcome (e.g., length of life only) is not
helpful if quality adjusted life years is what patients want from their
treatment of non-curable disease. Lastly, considering only Total
Beneﬁt and Cost is not optimal when selecting the right amount
of chemo. What matters is the extra beneﬁt and extra cost (i.e., MB
and MC)  that are derived from considering decreases (or increases)
in chemo for non-curable disease. When patients are being treated
with the “right” amount of chemo then a little more (or a little less)
helps the patient as much as it hurts the patient; this is where we
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should stop from a patient’s perspective. If patients value hope,
healthcare payers may  be pressured to pay for expensive chemo
regimens to provide it [28]. Intrinsically, there is nothing wrong
with paying for hope; however, efﬁcient use of scarce resources
would dictate that one should look for efﬁcient and cost-effective
ways to give real hope to individuals. Also, from a population or
a provider’s perspective, there may  be different answers to ques-
tions about correct comparator to use, QALYs gained, or amount of
chemo to equate MB  and MC.
4.2. Strengths and limitations
There are limitations associated with our work. Obviously, there
are other relevant concepts from health economics that were
not directly discussed (e.g., opportunity cost [29–31], incentives
[32–37]). More fulsome discussions of how to apply economic
thinking to healthcare appear elsewhere [38,39]. In addition, some
readers may  be critical of the need for calculation to determine opti-
mality, arguing that assumptions limit the practical use of these
concepts. To illustrate some of the concepts, we did make sim-
plifying assumptions (e.g., the linear, negative trade-off between
quality of life and length of life). However, many of the concepts
apply with less simplistic speciﬁcations or in circumstances where
additional chemo is associated with both additional gains in length
of life and quality of life. Also, we may  never know the exact speciﬁ-
cation of the speciﬁc functional form for Total Beneﬁt and Total Cost
equations. However, one may  not need calculus to prove that dying
in the emergency room from a chemo related adverse event dur-
ing the last stage of metastatic disease may  not be optimal; clearly
the marginal beneﬁt of treatment is not worth the marginal cost.
It is the concepts, not the calculations that are of value. The next
challenge in cancer care for non-curable disease will be to apply
them.
5. Conclusion
The economic perspective on cancer care when a cure is not
possible is beneﬁcial because it forces a focus on objectives and
constraints. We  reviewed and applied the concepts of “Choice of
Comparator”, “Use of QALYs” and “Equating MB  to MC”, demon-
strating how they ﬁt when considering the question of the optimal
amount of chemo for non-curable disease. Many current efforts
underway to improve healthcare can be viewed as applications of
these key economic principles e.g., the ABIM Foundation’s Choos-
ing Wisely [40], the Institute for Healthcare Improvement’s Triple
Aim [41], the pan-Canadian Oncology Drug Review’s Deliberative
Framework [42], or the Cancer Drug Fund in the UK [43,44]. While
it may  be difﬁcult to quantify when applying some of the concepts,
the true value is in the concepts themselves (not in the calculation).
However, it is important to remember that perspectives differ, so
different “optimal” amounts of chemo may  exist and these may  vary
by perspective. Healthcare is tricky because our aim may  be to make
everyone live longer and better, but we cannot afford that for every-
one; we must ﬁnd a way, within publicly funded health systems to
deﬁne how much society and individuals are willing to sacriﬁce to
live longer and better. And, in some cases, living better may  include
using scarce healthcare resources to foster a stronger sense of hope.
Health economics provides some structures to debate healthcare
spending; they are imperfect, but deﬁning best care for patients
and a population is never easy.
To many, it is clear that cancer drug costs are of concern
[6,45–48]. However, even for patients with non-curable disease
who are fully insured or independently wealthy, there is a scarce
resource and that is quality time. For them, even with chemo that
has zero ﬁnancial toxicity, best may  not be most [49].
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